Research Progress on Role of Gene Mutations in Prognostic Evaluation of Patients with Myelodysplastic Syndrome after Stem-Cell Transplantation--Review.
10.19746/j.cnki.issn.1009-2137.2019.04.056
- Author:
Yu-Mei HU
1
;
Sen CUI
2
;
Lin-Hua JI
3
Author Information
1. Department of Hematology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China.
2. Department of Hematology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China E-mail: 13897284366@139.com.
3. Department of Hematology, Qinghai University Affiliated Hospital, Xining 810000, Qinghai Province, China E-mail: 13997244508@163.com.
- Publication Type:Journal Article
- MeSH:
Hematopoietic Stem Cell Transplantation;
Humans;
Mutation;
Myelodysplastic Syndromes;
Prognosis;
Stem Cell Transplantation
- From:
Journal of Experimental Hematology
2019;27(4):1330-1333
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Myelodysplastic syndromes (MDS) represent a clonal hematopoietic stem cell disorder characterized by morphologic features of dyspoiesis, high risk of transformation from MDS into AML. Allogeneic hematopoietic stem-cell transplantation is the only curative therapy for MDS, but the failure rate of transplantation is still high, which attribute to relapsed disease and transplant-related complications. Recently, the spectrum of gene abnormalities in MDS has been revealed by next generation genomic sequencing techniques. It was found that more than 80% MDS patients have at least one gene mutation. Mutated genes in MDS are powerfully associated with clinical phenotype and prognosis. In this review , the recent advancements regarding recurrent gene mutations in MDS are briefly summarized, and the prognostic values of gene mutations are discussed in MDS or after allogeneic hematopoietic stem-cell transplantation,so as to set up a predicting model and to guide the treatment.
